This month, the president and chief executive officer of Green Shield Canada, the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”
Earlier this year, British Columbia became the first Canadian province to mandate that patients currently taking reference biologics for rheumatology indications and for diabetes must be switched to biosimilars over a 6-month period.
The policy will affect patients covered under PharmaCare, a publicly funded national drug coverage program; in Canada, prescription drug coverage is split between public programs for those 65 or older, in long-term care, or without income, while private, employer-based coverage applies to all others.
This month, the president and chief executive officer of Green Shield Canada (GSC), the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”
Writing in an op-ed in The Globe and Mail, GSC’s Zahid Salman explained that, as innovative drugs, such as gene and cell therapies, enter the marketplace with ever-higher price tags, payers both public and private have had to make increasingly difficult decisions about which drugs are covered. Biosimilars, wrote Salman, represent a logical means by which to provide patients with effective care at a fraction of the price, helping to promote a sustainable healthcare system for Canadian patients.
However, the continued dominance of brand-name infliximab, Remicade, in the Canadian market after the entry of biosimilar options “paints a picture of financially interested parties driven to extreme measures to protect profits and sales, resorting to generating fear around the progress biosimilars represent.” The resulting low uptake of biosimilars, he added, has diminished the opportunity to promote sustainability without compromising patient care.
Salman writes that GSC applauds British Columbia for its decision to implement its biosimilar program, and he called on other provincial governments to take the same approach as a step toward greater healthcare sustainability.
GSC has been an early champion of biosimilars in the Canadian context; in 2016, the company started to give biosimilars preferred product listings on formularies, and in 2018, the payer launched a pilot switching program under which patients already treated with biologics were transitioned to biosimilars. The program, which was optional for GSC’s clients, has been highly successful, as reported previously, and patients were largely accepting of the switch.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.